HeartSciences gains cash via Series D, converts debt; pre-commercial, diluted, going-concern

Snapshot - HeartSciences Inc. (NASDAQ: HSCSW)

Here's what's happening inside the company, with the income-statement positives and negatives up front and the key facts/statistics beneath.

Quick read - the headlines

* The company remains pre-commercial in the U.S.; revenue is effectively negligible ($1,900 this quarter).
* Management raised cash in Q1 via a Series D unit offering and debt-to-equity exchanges, which boosted cash and equity but materially diluted share count.
* Losses continue (~$2.05M this quarter) and auditors/management flag substantial doubt about going concern; internal control weaknesses remain.

Income statement - positive aspects

* Operating expense control: total operating expenses fell 10% year-over-year ($1.875M vs $2.076M) driven mainly by a 19% reduction in R&D ($997k vs $1.225M).
* Per-share loss improved materially because weighted-average shares rose (dilution), reducing loss per share to $(1.58) from $(2.64).
* Non-cash stock-based compensation is being used for retention/compensation (stock comp expense $174.6k), which preserves cash.

Income statement - negative aspects

* Net loss stable and large: $2.055M for the quarter; company still operating at a high burn rate.
* Interest expense spiked to $183.7k (vs $22.5k prior year) - largely non-cash amortization of OID and debt-service costs tied to the Streeterville note, increasing financing cost pressure.
* Revenue remains immaterial (device sales outside U.S. only): $1.9k this quarter - no meaningful commercial revenue until FDA clearance and broader launches.
* Other income fell sharply (from $46.5k to $2.8k), removing a modest offset to costs this year.

Key numbers & facts (Q1 ended July 31, 2025 - factual)

* Cash and cash equivalents: $2,792,231 (up $1,694,133 vs Apr 30, 2025).
* Total assets: $6,437,186 (vs $4,222,909).
* Total liabilities: $3,296,075 (down from $4,017,738).
* Stockholders' equity: $3,141,111 (vs $205,171) - increase driven by Series D issuance, conversions and equity for debt exchanges.
* Accumulated deficit: $(78,182,629) (vs $(76,127,635)).
* Revenues: $1,900 (vs $0). Cost of sales $760; gross margin $1,140.
* R&D expense: $997,206 (down $228k YoY). SG&A: $878,053 (up $27k YoY).
* Loss from operations: $(1,874,119). Net loss: $(2,054,994). Net loss per share: $(1.58). Weighted avg. shares: 1,303,532.
* Cash flow - operating activities used $1,953,367. Financing provided $3,648,314 (primarily Series D unit proceeds).
* Series D Units issued in Q1: 1,317,689 Units for gross proceeds ≈ $4.6M; subsequent to period 238,720 Units for ≈ $0.8M. ~ $9.6M capacity remains in that offering at issuance date.
* Streeterville note: original principal $2,510,000; during the period $1,020,000 principal exchanged for 274,159 common shares; subsequent principal exchanges and repayments continued (see subsequent events). Unamortized OID + deferred financing costs ≈ $264k at July 31, 2025; amortization expense ≈ $110k during the quarter.
* Deferred tax assets $15.46M with full valuation allowance (net deferred tax assets $0).
* Accumulated federal NOLs ≈ $58M (beginning to expire in 2028 per the filings).

Corporate & operational items to watch

* Liquidity / going concern: management says current resources are insufficient to reach commercialization; they plan to raise more capital (equity, debt, partnerships). Substantial doubt flagged by auditor.
* Nasdaq listing risk: company received notice for failure to meet minimum stockholders' equity; Nasdaq granted extension through Sept 15, 2025 (filed plan to regain compliance).
* Regulatory path: MyoVista wavECG device submission expected in calendar 2025; algorithm submissions expected thereafter (low EF algorithm aimed H1 2026).
* Tech/regulatory progress: USPTO granted a foundational patent (June 2025); FDA granted Breakthrough Device designation for an aortic stenosis ECG algorithm (June 2025) - positive validation of IP/technology.
* Internal controls: disclosure controls judged not effective; material weaknesses identified (approval/review processes, insufficient GAAP resources, staffing/segregation of duties). This raises reporting risk until remediated.

Pros and cons for investors / stakeholders (brief)

* Pros: meaningful recent financing extended runway; patent and Breakthrough designation strengthen IP and regulatory profile; lower R&D run-rate this quarter; debt being converted to equity reduces near-term cash interest burden.
* Cons: no meaningful revenue yet; ongoing quarterly losses and high cash burn; interest/amortization from the Streeterville financing increases reported expense; share dilution is substantial and likely to continue if more capital is needed; Nasdaq compliance risk and going concern raise execution risk.

Bottom line: HeartSciences (NASDAQ: HSCSW) is an early-stage med-tech company that made near-term financing progress this quarter, improving cash and equity but at the cost of dilution and higher reported financing charges. Clinical/regulatory progress (patent, FDA Breakthrough designation) is encouraging, but commercial revenue is still absent and the company remains a financing story until FDA clearances and scalable revenue follow. Keep a close eye on cash runway, future equity issuance, Nasdaq compliance updates, and any FDA submission/clearance milestones.